Table 1 Overall results from 3-months CDI surveillance in the Czech Republic; CDI Clostridium difficile infection, CI confidential interval
Clostridium (Clostridioides) difficile infections (CDI) by type, 16 hospitals, 10–12/2017 | Number (%) | Mean incidence density (95% CI) |
|---|---|---|
CDI cases | 433 (100) | 4.5 [95% CI 3.6–5.2] |
Healthcare-associated CDIs | 330 (76.2) | 3.5 [95% CI 2.8–4.1] |
Community-associated and unknown origin CDIs | 52 (12.0) | 0.5 [95% CI 0.3–0.8] |
Recurrent CDI | 51 (11.8) | 0.5 [95% CI 0.3–0.7] |
Complicated course | 65 (15.0) | |
Death | 88 (20.3) | |
Characterisation of C. difficile isolates, 16 hospitals, 10–12/2017 | 379 (87.5) | |
Ribotyping and toxin genes detection | ||
Ribotype 001 | 127 (33.5) | |
Ribotype 176 | 44 (11.6) | |
Others (30 profiles) | 208 (54.9) | |
Binary toxin genes positive | 75 (19.8) | |
Antimicrobial susceptibility testing | Susceptible (%) | Reduced susceptibility (%) |
Metronidazole (breakpoint 2 mg/L) | 360 (95.0) | n = 19 (5.0), RTs: 001 n = 8, 027 n = 6, 176 n = 5 |
Vancomycin (breakpoint 2 mg/L) | 377 (99.5) | n = 2 (0.5), RTs: 001, 012 n = 1, each |
Moxifloxacin (breakpoint 4 mg/L) | 193 (50.9) | n = 186 (49.1), RTs: 001 n = 114, 002 n = 1, 012 n = 8, 017 n = 1, 027 n = 9, 033 n = 1, 078 n = 2, 126 n = 3, 176 n = 44, unrecognized n = 3 |